Block listing 6 Monthly Return

Shield Therapeutics PLC

02 January 2026

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Block Listing 6 Monthly Return

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics Retention Share Plan
Period of return:	From:	01 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		39,794
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		39,794

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics plc 2016 Company Share Option Plan
Period of return:	From:	01 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		341,020
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		341,020

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		The Shield Therapeutics plc 2016 Long Term Incentive Plan
Period of return:	From:	01 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		24,273
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		24,273

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics Retention and Performance Share Plan
Period of return:	From:	01 July 2025	To:	31 December 2025
Balance of unallotted securities under scheme(s) from previous return:		2,870,838
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		15,000,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		6,137,791
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		11,733,071

Name of contact:	Lucy Huntington-Bailey
Telephone number of contact:	[phone]

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Anders Lundstrom, CEO Santosh Shanbhag, CFO Lucy Huntington-Bailey, Company Secretary	[phone] [e-mail]
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Christoper Golden	[phone]
Joint Broker Cavendish Ltd Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward	[phone]

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU® is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics. 

 

END